Novo Nordisk Stock Rises as Q4 Wegovy Sales More Than Double
1. Novo Nordisk shares rise 4% on better-than-expected quarterly results. 2. Fourth-quarter sales increased 30% to DKK85.68 billion, exceeding analyst estimates. 3. CagriSema regulatory approval filing anticipated in Q1 2026 amid competition. 4. 2025 sales growth projected at 16%-24%, lower than 2024's 26%.